A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its…
An institutional-grade, numbers-driven thesis on ATTO — generated on demand from live fundamentals, scores and forecast.
Member feature · 7-day free trial · no charge today · cancel anytime
As of August 8, 2026, TradersQuant's model rates Attovia Therapeutics, Inc. (ATTO) 50/100 with a 12-month base-case forecast of $18.02 — -10.7% versus the current price of $20.17. Attovia Therapeutics, Inc. trades at $20.17 in the Healthcare sector. The score blends valuation, growth, earnings quality and momentum into a single grade.
The 12-month TradersQuant model price target for ATTO is $18.02, implying -10.7% versus the current price. The model's 12-month scenario range runs from $14.99 (bear) to $22.04 (bull), with a base case of $18.02.
On the fundamentals, Attovia Therapeutics shows a P/E of -22.9, trailing revenue of $1.4M, revenue growth of +0.0% YoY. This page also tracks ATTO's short interest, institutional (smart-money) positioning and the options market — the same cross-signal view institutions watch.
ATTO currently carries a TradersQuant composite score of 50/100, which we read as a cautious signal. Our 12-month price target of $18.02 implies -10.7% from $20.17. This is research, not financial advice — always combine it with your own judgement.
The TradersQuant 12-month model price target for ATTO is $18.02, about -10.7% versus the latest price of $20.17.
TradersQuant's 12-month model forecast for ATTO is a base case of $18.02, ranging from $14.99 (bear) to $22.04 (bull), an expected return of -10.7%. Forecasts are model estimates, not guarantees.
The TradersQuant price prediction for ATTO over the next 12 months is $18.02 in the base case (bear $14.99, bull $22.04), versus today's price of $20.17. Unlike black-box prediction sites, every TradersQuant call is logged at the price and date it was made and graded publicly against the S&P 500.
We deliberately don't publish 2030 price predictions for ATTO — no model can honestly forecast a single stock five-plus years out, and sites that do are guessing. TradersQuant focuses on a rigorous 12-month bull/base/bear range, refreshed continuously and graded on our public track record.
TradersQuant estimates ATTO's fair value at $25.19, implying +24.9% of expected upside versus the current price.
Attovia Therapeutics does not currently pay a dividend.
Data and model outputs are for research only and are not financial advice. Figures update continuously.
